

## Announced Insider Trading

Dr. Michael Diefenbeck, Chief Medical Officer and EVP Clinical Affairs, has sold 30,000 shares, with the sole purpose to cover tax effects of the distributed shares from the employee 2016 stock options program. After the transaction, his total ownership of shares in BONESUPPORT™ has increased with 24,000 shares to 108,160.

### For more information contact:

---

BONESUPPORT Holding AB  
Emil Billbäck, CEO  
+46 (0) 46 286 53 70

Håkan Johansson, CFO  
+46 (0) 46 286 53 70  
[ir@bonesupport.com](mailto:ir@bonesupport.com)

Cord Communications  
Charlotte Stjerngren  
+46 (0) 708 76 87 87  
[charlotte.stjerngren@cordcom.se](mailto:charlotte.stjerngren@cordcom.se)  
[www.cordcom.se](http://www.cordcom.se)

### About BONESUPPORT™

---

BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs. BONESUPPORT's bone graft substitutes are based on the patented technology platform **CERAMENT**. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 591 million in 2023. Please visit [www.bonesupport.com](http://www.bonesupport.com) for more information.

BONESUPPORT and CERAMENT are **registered trademarks** of BONESUPPORT AB.

### Attachments

---

### [Announced Insider Trading](#)